298380.KQ
Strong SellSinkerABL Bio Inc. · Healthcare · South Korea · $3.1B · Avg Vol: $11M/d
Sinker: Weak, expensive and falling. Nothing here to keep it afloat.
1
StockRankGet insider-trade alerts
QualityQuality
25
ValueValue
19
MomentumMomentum
6
P/E (TTM)
—
peers 16.4x
ROE
-44.3%
peers 0.3%
D/E
0.3x
peers 0.3x
Dividend %
—
trailing yield
ABOUT ABL BIO INC.
Read
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases.
FINANCIAL SUMMARY (KRW)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 67.3B | 65.5B | 33.4B | 79.3B | 5.6% | 33.5B | 89.0B | 146.2B | 35.8% |
| EPS (KRW) | 67.00 | -55.00 | -1,156 | -734.00 | — | -717.85 | — | — | — |
| Shares | 47.8M | 47.9M | 48.3M | 55.1M | +15.4% | 56.0M | — | — | — |
| Debt | 41.8B | 43.9B | 43.7B | 55.3B | 9.8% | 54.2B | — | — | — |
| Equity | 69.5B | 74.1B | 167.3B | 154.7B | 30.6% | — | — | — | — |
| Op CF | 72.1B | -28.4B | -69.4B | -41.3B | — | -40.8B | — | — | — |
| Inv CF | -71.2B | 29.9B | -47.2B | 62.1B | — | — | — | — | — |
| Fin CF | 4.6B | 1.4B | 144.6B | 32.5B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-43.1%
SMA 50SMA 200
Close
$37.33
RSI (14)
18.0
52W High
$189.97
From 52W High
0.2%
SCORE BREAKDOWN
Quality
25
ROIC
-23.4%27.7
ROE
-44.3%20.2
GP/Assets
13.3%31.7
Op. Margin
-85.3%17.8
FCF/Assets
n/mN/A
Piotroski
25.9
Int. Cover
-37.1x13.5
D/E Ratio
0.32x40.0
Current Ratio
1.72x32.6
Value
19
P/E (TTM)
—N/A
EV/EBITDA
-36.8x25.0
P/FCF
n/mN/A
P/B
20.3x5.0
P/S
91.5x6.9
Div Yield
—N/A
Momentum
6
52W High %
20%3.8
RS 6M
-93%1.0
SMA 50/200
0.52x2.5
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$3.1B
P/E (Forward)
261.4x
Gross Margin
99.7%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 298380.KQ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 298380.KQ | ABL Bio Inc.(you) | $3.1B | 1 | Strong Sell |
| 028300.KQ | HLB Co., Ltd. | $3.5B | 1 | Strong Sell |
| 141080.KQ | LigaChem Biosciences Inc. | $2.7B | 3 | Strong Sell |
| 310210.KQ | Voronoi, Inc. | $2.3B | 1 | Strong Sell |
| 347850.KQ | D&D Pharmatech Inc. | $1.8B | 1 | Strong Sell |
| 226950.KQ | OliX Pharmaceuticals, Inc | $1.6B | 3 | Strong Sell |
| 0126Z0.KS | Samsung Epis Holdings Co., Ltd. | $6.8B | 5 | Strong Sell |
| 302440.KS | SK bioscience Co.,Ltd. | $2.2B | 14 | Strong Sell |
| 475830.KQ | Orum Therapeutics, Inc. | $1.0B | 1 | Strong Sell |
| 127120.KQ | JS Link, Inc. | $854M | 9 | Strong Sell |
Peer medians: ROE 0.3% · P/E 16.4x · Gross margin 42.8%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.